Research Analysts Offer Predictions for NKTR Q2 Earnings

Key Points

• Analysts at Zacks Research have increased their Q2 2026 earnings per share estimate for Nektar Therapeutics from ($3.26) to ($3.05), with a full-year FY2026 estimate of ($15.25) EPS.
• Nektar Therapeutics reported a loss of ($2.95) EPS in its last quarterly earnings, surpassing analysts' expectations of ($3.13) by $0.18, with revenues of $11.18 million.
• The current consensus rating for Nektar Therapeutics is a "Moderate Buy" with a target price of $88.33, following positive updates from multiple equity analysts.

Nektar Therapeutics (NASDAQ:NKTR - Free Report) - Zacks Research increased their Q2 2026 EPS estimates for shares of Nektar Therapeutics in a note issued to investors on Thursday, September 4th. Zacks Research analyst Team now expects that the biopharmaceutical company will earn ($3.05) per share for the quarter, up from their prior estimate of ($3.26). The consensus estimate for Nektar Therapeutics' current full-year earnings is ($0.72) per share. Zacks Research also issued estimates for Nektar Therapeutics' Q3 2026 earnings at ($4.72) EPS, Q4 2026 earnings at ($4.64) EPS, FY2026 earnings at ($15.25) EPS, Q1 2027 earnings at ($3.42) EPS, Q2 2027 earnings at ($3.52) EPS and FY2027 earnings at ($18.26) EPS.

Several other research analysts have also recently weighed in on the stock. BTIG Research increased their price target on shares of Nektar Therapeutics from $60.00 to $100.00 and gave the company a "buy" rating in a report on Tuesday, June 24th. HC Wainwright increased their price target on shares of Nektar Therapeutics to $120.00 and gave the company a "buy" rating in a report on Tuesday, June 24th. Finally, B. Riley increased their price target on shares of Nektar Therapeutics from $60.00 to $85.00 and gave the company a "buy" rating in a report on Tuesday, July 8th. Six analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, Nektar Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $88.33.

Nektar Therapeutics Price Performance

Nektar Therapeutics stock traded up $1.48 during trading hours on Monday, hitting $48.68. The company had a trading volume of 848,765 shares, compared to its average volume of 1,095,591. The firm has a market cap of $925.89 million, a PE ratio of -5.53 and a beta of 1.06. Nektar Therapeutics has a one year low of $6.45 and a one year high of $50.53. The firm has a 50-day moving average of $28.01 and a 200 day moving average of $17.51.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($2.95) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($3.13) by $0.18. The company had revenue of $11.18 million for the quarter, compared to analysts' expectations of $9.42 million. Nektar Therapeutics had a negative net margin of 163.17% and a negative return on equity of 631.43%.

Insider Buying and Selling

In other Nektar Therapeutics news, insider Jonathan Zalevsky sold 1,721 shares of the stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $33.52, for a total transaction of $57,687.92. Following the transaction, the insider owned 17,462 shares in the company, valued at $585,326.24. This represents a 8.97% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Howard W. Robin sold 6,666 shares of the stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $46.69, for a total transaction of $311,235.54. Following the transaction, the chief executive officer owned 49,342 shares in the company, valued at approximately $2,303,777.98. The trade was a 11.90% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 25,178 shares of company stock worth $938,776. Company insiders own 5.25% of the company's stock.

Institutional Trading of Nektar Therapeutics

Several large investors have recently made changes to their positions in the company. FNY Investment Advisers LLC purchased a new stake in shares of Nektar Therapeutics during the second quarter worth $39,000. Headlands Technologies LLC purchased a new stake in shares of Nektar Therapeutics during the second quarter worth $65,000. IFP Advisors Inc purchased a new stake in shares of Nektar Therapeutics during the second quarter worth $124,000. Price T Rowe Associates Inc. MD lifted its position in shares of Nektar Therapeutics by 6.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 192,978 shares of the biopharmaceutical company's stock worth $180,000 after acquiring an additional 10,941 shares in the last quarter. Finally, Northern Trust Corp lifted its position in shares of Nektar Therapeutics by 0.9% during the fourth quarter. Northern Trust Corp now owns 1,414,984 shares of the biopharmaceutical company's stock worth $1,316,000 after acquiring an additional 12,826 shares in the last quarter. Institutional investors and hedge funds own 75.88% of the company's stock.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.